$NOVN,
The Novan Inc. (NOVN) Lowered by the Zacks Investment Research to “Sell”
February 25, 2017 Susan G. Crespo
The Novan Inc. (NOVN) Lowered by the Zacks Investment Research to “Sell”
Zacks Investment Research downgraded shares of Novan Inc. (NASDAQ:NOVN) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company’s product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through Nitricil technology(TM). Novan, Inc. is based in Durham, United States. “
A number of other brokerages also recently weighed in on NOVN. Wedbush reiterated an outperform rating and set a $33.00 price target on shares of Novan in a report on Tuesday, November 29th. Credit Suisse Group AG assumed coverage on Novan in a report on Monday, October 17th. They set an outperform rating and a $18.97 price target on the stock. JMP Securities assumed coverage on Novan in a report on Monday, October 17th. They set an outperform rating and a $31.00 price target on the stock. Finally, Piper Jaffray Cos. assumed coverage on Novan in a report on Monday, October 17th. They set an overweight rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Novan has a consensus rating of Buy and a consensus target price of $26.99.
Shares of Novan (NASDAQ:NOVN) opened at 27.12 on Tuesday. The company’s 50 day moving average price is $24.80 and its 200 day moving average price is $22.61. Novan has a one year low of $13.77 and a one year high of $30.90. The stock’s market capitalization is $432.24 million.
Novan (NASDAQ:NOVN) last issued its earnings results on Monday, November 14th. The company reported ($5.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.40) by $4.36. During the same period last year, the business posted ($2.66) earnings per share. On average, equities analysts expect that Novan will post ($10.77) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of NOVN. Partner Investment Management L.P. purchased a new position in shares of Novan during the third quarter worth approximately $141,000. Abingworth LLP purchased a new position in shares of Novan during the third quarter worth approximately $4,032,000. Spark Investment Management LLC purchased a new position in shares of Novan during the third quarter worth approximately $228,000. Emerald Acquisition Ltd. purchased a new position in shares of Novan during the third quarter worth approximately $537,000. Finally, Monashee Investment Management LLC purchased a new position in shares of Novan during the third quarter worth approximately $1,514,000. Hedge funds and other institutional investors own 14.60% of the company’s stock.
Novan Company Profile
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
Get a free copy of the Zacks research report on Novan (NOVN)
The Novan Inc. (NOVN) Lowered by the Zacks Investment Research to “Sell”
February 25, 2017 Susan G. Crespo
The Novan Inc. (NOVN) Lowered by the Zacks Investment Research to “Sell”
Zacks Investment Research downgraded shares of Novan Inc. (NASDAQ:NOVN) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company’s product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through Nitricil technology(TM). Novan, Inc. is based in Durham, United States. “
A number of other brokerages also recently weighed in on NOVN. Wedbush reiterated an outperform rating and set a $33.00 price target on shares of Novan in a report on Tuesday, November 29th. Credit Suisse Group AG assumed coverage on Novan in a report on Monday, October 17th. They set an outperform rating and a $18.97 price target on the stock. JMP Securities assumed coverage on Novan in a report on Monday, October 17th. They set an outperform rating and a $31.00 price target on the stock. Finally, Piper Jaffray Cos. assumed coverage on Novan in a report on Monday, October 17th. They set an overweight rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Novan has a consensus rating of Buy and a consensus target price of $26.99.
Shares of Novan (NASDAQ:NOVN) opened at 27.12 on Tuesday. The company’s 50 day moving average price is $24.80 and its 200 day moving average price is $22.61. Novan has a one year low of $13.77 and a one year high of $30.90. The stock’s market capitalization is $432.24 million.
Novan (NASDAQ:NOVN) last issued its earnings results on Monday, November 14th. The company reported ($5.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.40) by $4.36. During the same period last year, the business posted ($2.66) earnings per share. On average, equities analysts expect that Novan will post ($10.77) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of NOVN. Partner Investment Management L.P. purchased a new position in shares of Novan during the third quarter worth approximately $141,000. Abingworth LLP purchased a new position in shares of Novan during the third quarter worth approximately $4,032,000. Spark Investment Management LLC purchased a new position in shares of Novan during the third quarter worth approximately $228,000. Emerald Acquisition Ltd. purchased a new position in shares of Novan during the third quarter worth approximately $537,000. Finally, Monashee Investment Management LLC purchased a new position in shares of Novan during the third quarter worth approximately $1,514,000. Hedge funds and other institutional investors own 14.60% of the company’s stock.
Novan Company Profile
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
Get a free copy of the Zacks research report on Novan (NOVN)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
